行動指針
行動指針
GSK企業行動指針
贈収賄防止（ABAC）プログラム
贈収賄防止（ABAC）プログラムは、贈収賄の脅威ならびにリスクに対するGSKの対策の一環です。このプログラムにはABACハンドブックが含まれており、これは社内外の関係者が贈収賄のリスクを理解し、贈収賄行為あるいは贈収賄とみなされる行為のどちらに対しても積極的に対抗するべく、各々の責任を明確化するために作成されたものです。
贈収賄防止プログラム取引先・協業先向けガイドライン
当社の贈収賄防止ポリシーならびにビジネスパートナーとして取引先・協業先に期待するものを知っていただくために、GSKとかかわりのあるすべての第三者に取引先・協業先向けガイドラインを配布します。
Public policies
GSK access and developing countries
- Developing world vaccine production technology transfer
- IP and access to medicines in developing countries
- Technology transfer, capacity building and developing countries
- Non-communicable diseases and the developing world
- The post 2015 development agenda
- Universal healthcare coverage
- Civil society organisations and vaccine procurement
- Working together for the health of mothers and children
GSK and research & development
- Clinical trials in the developing world
- Incentivising antibacterial R&D
- Cloning technologies and stem cell research
- The convention on biological diversity
- Disclosure of clinical trial information
- The care, welfare and treatment of animals
- The role of transgenic animals in biomedical research
- Use of Non-human Primates (NHPs) in the Discovery and Development of Medicines and Vaccines
GSK and intellectual property
- Incremental innovation
- Compulsory licences
- Evergreening
- Proposals for a disclosure in patent applications
- Regulatory data protection
GSK and the environment
- Hazardous chemical management
- Genetically modified micro-organisms and Environment, Health and Safety (EHS)
- GSK and REACH
- Nanotechnology
- Ozone depletion and metered-dose inhalers for asthma
- Pharmaceuticals in environment
- The impact of climate change on health
- Use of ozone depleting substances in ancillary plant and equipment
GSK and public health
- Counterfeiting of healthcare products
- Pharmacovigilance
- Paediatric medicines
- Tiered pricing & vaccines
- Pandemic preparedness
- Information to patients
GSK and other issues